Drug Patents owned by Novartis

1. List of Afinitor drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8778962 NOVARTIS Treatment of solid tumors with rapamycin derivatives
Feb, 2022

(11 months ago)

US8436010 NOVARTIS Treatment of solid tumors with rapamycin derivatives
Feb, 2022

(11 months ago)

US8778962

(Pediatric)

NOVARTIS Treatment of solid tumors with rapamycin derivatives
Aug, 2022

(5 months ago)

US8436010

(Pediatric)

NOVARTIS Treatment of solid tumors with rapamycin derivatives
Aug, 2022

(5 months ago)

US8410131 NOVARTIS Cancer treatment
Nov, 2025

(2 years from now)

US8410131

(Pediatric)

NOVARTIS Cancer treatment
May, 2026

(3 years from now)

US9006224 NOVARTIS Neuroendocrine tumor treatment
Jul, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Feb 26, 2023

Drugs and Companies using EVEROLIMUS ingredient

Market Authorisation Date: 30 March, 2009

Treatment: Treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected.; Treatment of advanced hormone receptor positive, her2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole; Treatment of solid excretory system tumors; Advanced renal cell carcinoma (rcc), after failure of treatment with sunitinib or sorafenib; Treatment of patients with progessive neuroendocrine tumors of pancreatic origin (pnet) that are unresectable, locally advanced or metastatic

Dosage: TABLET;ORAL

How can I launch a generic of AFINITOR before it's patent expiration?
More Information on Dosage

2. List of Amturnide drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8183295 NOVARTIS Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
May, 2023

(3 months from now)

Drugs and Companies using ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE ingredient

Market Authorisation Date: 21 December, 2010

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

3. List of Arcapta Neohaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6878721 NOVARTIS Beta2-adrenoceptor agonists
Feb, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8479730 NOVARTIS Inhaler device
Oct, 2028

(5 years from now)

Drugs and Companies using INDACATEROL MALEATE ingredient

Market Authorisation Date: 01 July, 2011

Treatment: The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema

Dosage: POWDER;INHALATION

More Information on Dosage

4. List of Ciprodex drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9402805 NOVARTIS Method of treating middle ear infections
Sep, 2022

(4 months ago)

US9149486 NOVARTIS Method of treating middle ear infections
Sep, 2022

(4 months ago)

US9345714 NOVARTIS Method of treating middle ear infections
Sep, 2022

(4 months ago)

US8846650 NOVARTIS Method of treating middle ear infections
Jun, 2025

(2 years from now)

Drugs and Companies using CIPROFLOXACIN; DEXAMETHASONE ingredient

Market Authorisation Date: 18 July, 2003

Treatment: Treatment of acute otitis media; Treatment of acute otitis externa

Dosage: SUSPENSION/DROPS;OTIC

How can I launch a generic of CIPRODEX before it's patent expiration?
More Information on Dosage

5. List of Exforge Hct drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101599 NOVARTIS Pharmaceutical composition containing anti-hypertensive agents
May, 2023

(3 months from now)

US8475839 NOVARTIS Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same
May, 2023

(3 months from now)

US8475839

(Pediatric)

NOVARTIS Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same
Nov, 2023

(9 months from now)

Drugs and Companies using AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN ingredient

Market Authorisation Date: 30 April, 2009

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of EXFORGE HCT before it's patent expiration?
More Information on Dosage

6. List of Gilenya drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8324283 NOVARTIS Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol
Mar, 2026

(3 years from now)

US8324283

(Pediatric)

NOVARTIS Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol
Sep, 2026

(3 years from now)

US9187405 NOVARTIS S1P receptor modulators for treating relasping-remitting multiple sclerosis
Jun, 2027

(4 years from now)

US10543179 NOVARTIS Dosage regimen of an S1P receptor modulator
Dec, 2027

(4 years from now)

US9187405

(Pediatric)

NOVARTIS S1P receptor modulators for treating relasping-remitting multiple sclerosis
Dec, 2027

(4 years from now)

US9592208 NOVARTIS Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
Mar, 2032

(9 years from now)

US9592208

(Pediatric)

NOVARTIS Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
Sep, 2032

(9 years from now)

Drugs and Companies using FINGOLIMOD HYDROCHLORIDE ingredient

Market Authorisation Date: 21 September, 2010

Treatment: Treatment of relapsing-remitting sclerosis (ms); Treatment of relapsing remitting multiple sclerosis by determining varicella zoster virus (vzv) status and vaccinating prior to commencing treatment; Treatment of multiple sclerosis in the pediatric patient population with 0.25 mg fingolimod

Dosage: CAPSULE;ORAL

How can I launch a generic of GILENYA before it's patent expiration?
More Information on Dosage

7. List of Gleevec drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6958335

(Pediatric)

NOVARTIS Treatment of gastrointestinal stromal tumors
Jun, 2022

(7 months ago)

Drugs and Companies using IMATINIB MESYLATE ingredient

Market Authorisation Date: 18 April, 2003

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of GLEEVEC before it's patent expiration?
More Information on Dosage

8. List of Hycamtin drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8158645 NOVARTIS Compound, corresponding compositions, preparation and/or treatment methods
Dec, 2024

(1 year, 10 months from now)

Drugs and Companies using TOPOTECAN HYDROCHLORIDE ingredient

Market Authorisation Date: 11 October, 2007

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

9. List of Ilevro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7947295 NOVARTIS Ophthalmic compositions containing a synergistic combination of two polymers
Jun, 2024

(1 year, 4 months from now)

US9662398 NOVARTIS Carboxylvinyl polymer-containing nanoparticle suspensions
Dec, 2030

(7 years from now)

US8921337 NOVARTIS Carboxyvinyl polymer-containing nanoparticle suspensions
Mar, 2032

(9 years from now)

Drugs and Companies using NEPAFENAC ingredient

Market Authorisation Date: 16 October, 2012

Treatment: NA

Dosage: SUSPENSION/DROPS;OPHTHALMIC

How can I launch a generic of ILEVRO before it's patent expiration?
More Information on Dosage

10. List of Izba drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9144561 NOVARTIS Pharmaceutical compositions having desirable bioavailability
Mar, 2029

(6 years from now)

US8754123 NOVARTIS Pharmaceutical compositions having desirable bioavailability
May, 2029

(6 years from now)

US8722735 NOVARTIS Pharmaceutical compositions having desirable bioavailability
Oct, 2029

(6 years from now)

US8178582 NOVARTIS Pharmaceutical compositions having desirable bioavailability
Oct, 2029

(6 years from now)

Drugs and Companies using TRAVOPROST ingredient

Market Authorisation Date: 15 May, 2014

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of IZBA before it's patent expiration?
More Information on Dosage

11. List of Kisqali drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8324225 NOVARTIS Pyrrolopyrimidine compounds and their uses
Jun, 2028

(5 years from now)

US8685980 NOVARTIS Pyrrolopyrimidine compounds and their uses
May, 2030

(7 years from now)

US8415355 NOVARTIS Pyrrolopyrimidine compounds and their uses
Mar, 2031

(8 years from now)

US9193732 NOVARTIS Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
Nov, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9416136 NOVARTIS Pyrrolopyrimidine compounds and their uses
Aug, 2029

(6 years from now)

US8962630 NOVARTIS Pyrrolopyrimidine compounds and their uses
Dec, 2029

(6 years from now)

US9868739 NOVARTIS Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
Nov, 2031

(8 years from now)

US10799506 NOVARTIS Ribociclib tablet
Apr, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 13, 2022
New Patient Population (NPP) Dec 10, 2024

Drugs and Companies using RIBOCICLIB SUCCINATE ingredient

NCE-1 date: March, 2021

Market Authorisation Date: 13 March, 2017

Treatment: In combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy; In combination with fulvestrant for the treatment of postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy; In combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer; In combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men, for the treatment of hr-positive, her2-negative advanced or metastatic breast cancer; In combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer

Dosage: TABLET;ORAL

How can I launch a generic of KISQALI before it's patent expiration?
More Information on Dosage

12. List of Kisqali Femara Co-pack (copackaged) drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8324225 NOVARTIS Pyrrolopyrimidine compounds and their uses
Jun, 2028

(5 years from now)

US8685980 NOVARTIS Pyrrolopyrimidine compounds and their uses
May, 2030

(7 years from now)

US8415355 NOVARTIS Pyrrolopyrimidine compounds and their uses
Mar, 2031

(8 years from now)

US9193732 NOVARTIS Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
Nov, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9416136 NOVARTIS Pyrrolopyrimidine compounds and their uses
Aug, 2029

(6 years from now)

US8962630 NOVARTIS Pyrrolopyrimidine compounds and their uses
Dec, 2029

(6 years from now)

US9868739 NOVARTIS Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
Nov, 2031

(8 years from now)

US10799506 NOVARTIS Ribociclib tablet
Apr, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 13, 2022
New Patient Population (NPP) Dec 10, 2024

Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient

NCE-1 date: March, 2021

Market Authorisation Date: 04 May, 2017

Treatment: Treatment of pre/perimenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; As initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer

Dosage: TABLET;ORAL

How can I launch a generic of KISQALI FEMARA CO-PACK (COPACKAGED) before it's patent expiration?
More Information on Dosage

13. List of Leqvio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9074213 NOVARTIS Compositions and methods for inhibiting expression of a target gene
Mar, 2022

(10 months ago)

US8546143 NOVARTIS Compositions and methods for inhibiting expression of a target gene
Apr, 2022

(9 months ago)

US8232383 NOVARTIS RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
Feb, 2023

(21 days from now)

US11078485 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Nov, 2023

(9 months from now)

US9708610 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Jan, 2024

(11 months from now)

US10273477 NOVARTIS Therapeutic compositions
Mar, 2024

(1 year, 1 month from now)

US10669544 NOVARTIS Therapeutic compositions
Mar, 2024

(1 year, 1 month from now)

US9708615 NOVARTIS Therapeutic compositions
Mar, 2024

(1 year, 1 month from now)

US8809292 NOVARTIS Compositions and methods for inhibiting expression of the PCSK9 gene
May, 2027

(4 years from now)

US10131907 NOVARTIS Glycoconjugates of RNA interference agents
Aug, 2028

(5 years from now)

US9370582 NOVARTIS Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(5 years from now)

US10806791 NOVARTIS Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(5 years from now)

US8828956 NOVARTIS Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(5 years from now)

US8106022 NOVARTIS Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2029

(6 years from now)

US10125369 NOVARTIS PCSK9 iRNA compositions and methods of use thereof
Aug, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10590418 NOVARTIS Methods and compositions for RNAi mediated inhibition of gene expression in mammals
Jul, 2022

(6 months ago)

US10266825 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Nov, 2023

(9 months from now)

US8222222 NOVARTIS Compositions and methods for inhibiting expression of the PCSK9 gene
Dec, 2027

(4 years from now)

US10851377 NOVARTIS Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder
Aug, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 22, 2026

Drugs and Companies using INCLISIRAN SODIUM ingredient

NCE-1 date: December, 2025

Market Authorisation Date: 22 December, 2021

Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascvd), by inhibiting expression of the pcsk9 gene

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

14. List of Mayzent drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7939519 NOVARTIS Immunosuppresant compounds and compositions
Aug, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8492441 NOVARTIS Dosage regimen of an S1P receptor agonist
Nov, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 26, 2024
M Mar 1, 2025

Drugs and Companies using SIPONIMOD FUMARIC ACID ingredient

NCE-1 date: March, 2023

Market Authorisation Date: 26 March, 2019

Treatment: A method of treating multiple sclerosis by administering siponimod using a titration scheme to reach a maintenance dose

Dosage: TABLET;ORAL

More Information on Dosage

15. List of Mekinist drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7378423 NOVARTIS Pyrimidine compound and medical use thereof
May, 2027

(4 years from now)

US8703781 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
Oct, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835443 NOVARTIS Pyrimidine compound and medical use thereof
Jun, 2025

(2 years from now)

US8952018 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors
Oct, 2030

(7 years from now)

US9399021 NOVARTIS Pharmaceutical composition
Jan, 2032

(9 years from now)

US9271941 NOVARTIS Pharmaceutical composition
Jan, 2032

(9 years from now)

US9155706 NOVARTIS Pharmaceutical composition
Jan, 2032

(9 years from now)

US8580304 NOVARTIS Pharmaceutical composition
Jan, 2032

(9 years from now)

US10869869 NOVARTIS Method of adjuvant cancer treatment
Aug, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 22, 2024
M Oct 6, 2022
New Indication (I) Jun 22, 2025

Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient

Market Authorisation Date: 29 May, 2013

Treatment: Mekinist is indicated, as a single agent or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an fda-approved test; Treatment of unresectable or metastatic melanoma; Mekinist is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test; In combination with dabrafenib for the treatment of unresectable or metastatic melanoma.; Mekinist is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfactory locoregional treatment options; Mekinist is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of lymph node(s), following complete resection; Mekinist(r) is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fda-approved test, and involvement of lymph node(s), following complete resection; Mekinist in combination with dabrafenib for the treatment of patients with unresectable or metastatic melanoma

Dosage: TABLET;ORAL

More Information on Dosage

16. List of Moxeza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9114168 NOVARTIS Pharmaceutical compositions containing a fluoroquinolone antibiotic drug
May, 2029

(6 years from now)

US8450311 NOVARTIS Pharmaceutical compositions containing a fluoroquinolone antibiotic drug
May, 2029

(6 years from now)

Drugs and Companies using MOXIFLOXACIN HYDROCHLORIDE ingredient

Market Authorisation Date: 19 November, 2010

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of MOXEZA before it's patent expiration?
More Information on Dosage

17. List of Nevanac drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8071648 NOVARTIS Topical nepafenac formulations
Dec, 2025

(2 years from now)

US8324281 NOVARTIS Topical nepafenac formulations
Dec, 2025

(2 years from now)

US7834059 NOVARTIS Topical nepafenac formulations
Jan, 2027

(4 years from now)

Drugs and Companies using NEPAFENAC ingredient

Market Authorisation Date: 19 August, 2005

Treatment: Method of treating ocular inflammation

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage

18. List of Patanase drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8399508 NOVARTIS Olopatadine formulations for topical nasal administration
Sep, 2022

(4 months ago)

US7977376 NOVARTIS Olopatadine formulations for topical nasal administration
Feb, 2023

(3 days from now)

US8399508

(Pediatric)

NOVARTIS Olopatadine formulations for topical nasal administration
Mar, 2023

(a month from now)

US7977376

(Pediatric)

NOVARTIS Olopatadine formulations for topical nasal administration
Aug, 2023

(6 months from now)

Drugs and Companies using OLOPATADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 April, 2008

Treatment: Allergic rhinitis

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of PATANASE before it's patent expiration?
More Information on Dosage

19. List of Piqray drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8476268 NOVARTIS Pyrrolidine-1,2-dicarboxamide derivatives
Sep, 2029

(6 years from now)

US8227462 NOVARTIS Pyrrolidine-1,2-dicarboxamide derivatives
Sep, 2030

(7 years from now)

CN102149711B NOVARTIS Organic Compounds
Sep, 2029

(6 years from now)

CN102149711A NOVARTIS Organic Compounds
Sep, 2029

(6 years from now)

IN307469B NOVARTIS The Compound (S)-Pyrrolidine-1,2-Dicarboxylic Acid 2-Amide-1- ({4-Methyl-5-[2-(2,2,2-Trifluoro-1,1-Dimethyl-Ethyl)- Pyridin-4-Yl]-Thiazol-2-Yl}-Amide)
Sep, 2029

(6 years from now)

EP2331537A1 NOVARTIS 1-((5-Heteroarylthiazol-2-Yl)Aminocarbonyl)Pyrrolidine-2-Carboxamide Derivatives As Phosphatidylinositol 3-Kinase (Pi3K) Inhibitors Useful In The Treatment Of Proliferative Diseases
Sep, 2029

(6 years from now)

EP2331537B1 NOVARTIS 1-((5-Heteroarylthiazol-2-Yl)Aminocarbonyl)Pyrrolidine-2-Carboxamide Derivatives As Phosphatidylinositol 3-Kinase (Pi3K) Inhibitors Useful In The Treatment Of Proliferative Diseases
Sep, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 24, 2024

Drugs and Companies using ALPELISIB ingredient

NCE-1 date: May, 2023

Market Authorisation Date: 24 May, 2019

Treatment: In combination with fulvestrant for treatment of postmenopausal women, and men, with hr-positive, her-2-negative, pik3ca-mutated, advanced or metastatic breast cancer

Dosage: TABLET;ORAL

More Information on Dosage

20. List of Promacta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7160870 NOVARTIS Thrombopoietin mimetics
Nov, 2022

(2 months ago)

US7547719 NOVARTIS 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)
Jul, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7160870

(Pediatric)

NOVARTIS Thrombopoietin mimetics
May, 2023

(3 months from now)

US7795293 NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
May, 2023

(3 months from now)

US7795293

(Pediatric)

NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Nov, 2023

(9 months from now)

US7547719

(Pediatric)

NOVARTIS 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)
Jan, 2026

(2 years from now)

US8052994 NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Aug, 2027

(4 years from now)

US8071129 NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Aug, 2027

(4 years from now)

US8052993 NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Aug, 2027

(4 years from now)

US8828430 NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Aug, 2027

(4 years from now)

US8062665 NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Aug, 2027

(4 years from now)

US8052994

(Pediatric)

NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Feb, 2028

(5 years from now)

US8828430

(Pediatric)

NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Feb, 2028

(5 years from now)

US8071129

(Pediatric)

NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Feb, 2028

(5 years from now)

US8062665

(Pediatric)

NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Feb, 2028

(5 years from now)

US8052993

(Pediatric)

NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Feb, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 16, 2025
Pediatric Exclusivity (PED) Feb 26, 2022

Drugs and Companies using ELTROMBOPAG OLAMINE ingredient

Market Authorisation Date: 20 November, 2008

Treatment: Patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy; Treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); Treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy; Treatment of idiopathic thrombocytopenic purpura (itp); Treatment of thrombocytopenia in adult and pediatric patients 6 years and older with chronic immune (idiopathic) thrombocytopenia (itp); Combination with immunosuppressive therapy for first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia

Dosage: TABLET;ORAL

How can I launch a generic of PROMACTA before it's patent expiration?
More Information on Dosage

21. List of Promacta Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7160870 NOVARTIS Thrombopoietin mimetics
Nov, 2022

(2 months ago)

US7547719 NOVARTIS 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)
Jul, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7160870

(Pediatric)

NOVARTIS Thrombopoietin mimetics
May, 2023

(3 months from now)

US7795293 NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
May, 2023

(3 months from now)

US7795293

(Pediatric)

NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Nov, 2023

(9 months from now)

US7547719

(Pediatric)

NOVARTIS 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)
Jan, 2026

(2 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 16, 2025
Pediatric Exclusivity (PED) Feb 26, 2022

Drugs and Companies using ELTROMBOPAG OLAMINE ingredient

Market Authorisation Date: 24 August, 2015

Treatment: Treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); Treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy; Patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy; Combination with immunosuppressive therapy for first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia

Dosage: FOR SUSPENSION;ORAL

How can I launch a generic of PROMACTA KIT before it's patent expiration?
More Information on Dosage

22. List of Reclast drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8052987 NOVARTIS Method of administering bisphosphonates
Oct, 2023

(8 months from now)

US7932241 NOVARTIS Pharmaceutical products comprising bisphosphonates
Feb, 2028

(5 years from now)

US7932241

(Pediatric)

NOVARTIS Pharmaceutical products comprising bisphosphonates
Aug, 2028

(5 years from now)

Drugs and Companies using ZOLEDRONIC ACID ingredient

Market Authorisation Date: 16 April, 2007

Treatment: Treatment and prevention of postmenopausal or glucocorticoid-induced osteoporosis and treatment to increase bone mass in men with osteoporosis

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of RECLAST before it's patent expiration?
More Information on Dosage

23. List of Rydapt drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222244 NOVARTIS Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
Oct, 2022

(3 months ago)

US7973031 NOVARTIS Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
Oct, 2028

(5 years from now)

US8575146 NOVARTIS Pharmaceutical uses of staurosporine derivatives
Dec, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 28, 2022
Orphan Drug Exclusivity (ODE) Apr 28, 2024

Drugs and Companies using MIDOSTAURIN ingredient

NCE-1 date: April, 2021

Market Authorisation Date: 28 April, 2017

Treatment: Treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) who are flt3 mutation-positive, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy; Treatment of adult patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with associated hematological neoplasm (sm-ahn), or mast cell leukemia (mcl)

Dosage: CAPSULE;ORAL

How can I launch a generic of RYDAPT before it's patent expiration?
More Information on Dosage

24. List of Scemblix drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8829195 NOVARTIS Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
May, 2033

(10 years from now)

US11407735 NOVARTIS Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
May, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 29, 2026
Orphan Drug Exclusivity (ODE) Oct 29, 2028

Drugs and Companies using ASCIMINIB HYDROCHLORIDE ingredient

NCE-1 date: October, 2025

Market Authorisation Date: 29 October, 2021

Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml)

Dosage: TABLET;ORAL

More Information on Dosage

25. List of Seebri drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8479730 NOVARTIS Inhaler device
Oct, 2028

(5 years from now)

US8182838 NOVARTIS Dry powder composition comprising co-jet milled particles for pulmonary inhalation
Oct, 2028

(5 years from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Market Authorisation Date: 29 October, 2015

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

26. List of Tafinlar drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8415345 NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
Jan, 2030

(6 years from now)

US7994185 NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
Jan, 2030

(6 years from now)

US8703781 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
Oct, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835443 NOVARTIS Pyrimidine compound and medical use thereof
Jun, 2025

(2 years from now)

US9233956 NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
May, 2029

(6 years from now)

US8952018 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors
Oct, 2030

(7 years from now)

US10869869 NOVARTIS Method of adjuvant cancer treatment
Aug, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 22, 2024
M Oct 6, 2022
New Indication (I) Jun 22, 2025

Drugs and Companies using DABRAFENIB MESYLATE ingredient

Market Authorisation Date: 29 May, 2013

Treatment: Tafinlar(r) is indicated, in combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test.; Tafinlar is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfactory locoregional treatment options; Tafinlar(r) is indicated, in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an fda-approved test.; Tafinlar is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of lymph node(s), following complete resection; Tafinlar is indicated, in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an fda-approved test.; Treatment of patients with unresectable or metastatic melanoma with braf v600e mutations after confirming the presence of braf v600e mutation; Tafinlar is indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with braf v600e mutation as detected by an fda-approved test; Tafinlar(r) is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fda-approved test, and involvement of lymph node(s), following complete resection; Treatment of melanoma; Tafinlar in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma

Dosage: CAPSULE;ORAL

More Information on Dosage

27. List of Tasigna drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7169791 NOVARTIS Inhibitors of tyrosine kinases
Jul, 2023

(5 months from now)

US8415363 NOVARTIS Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
Jul, 2026

(3 years from now)

US8163904 NOVARTIS Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide
Aug, 2028

(5 years from now)

US9061029 NOVARTIS Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity
Apr, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7169791

(Pediatric)

NOVARTIS Inhibitors of tyrosine kinases
Jan, 2024

(11 months from now)

US8501760 NOVARTIS Pharmaceutical compositions comprising nilotinib or its salt
Jul, 2026

(3 years from now)

US8389537 NOVARTIS Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
Jul, 2026

(3 years from now)

US8415363

(Pediatric)

NOVARTIS Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
Jan, 2027

(3 years from now)

US8389537

(Pediatric)

NOVARTIS Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
Jan, 2027

(3 years from now)

US8501760

(Pediatric)

NOVARTIS Pharmaceutical compositions comprising nilotinib or its salt
Jan, 2027

(3 years from now)

US8293756 NOVARTIS Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate
Sep, 2027

(4 years from now)

US8293756

(Pediatric)

NOVARTIS Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate
Mar, 2028

(5 years from now)

US8163904

(Pediatric)

NOVARTIS Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide
Feb, 2029

(6 years from now)

US9061029

(Pediatric)

NOVARTIS Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity
Oct, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 23, 2028
Pediatric Exclusivity (PED) Sep 22, 2025

Drugs and Companies using NILOTINIB HYDROCHLORIDE ingredient

Market Authorisation Date: 29 October, 2007

Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml); A method for the treatment of leukemias; Treatment of newly diagnosed philadelphia chromosome positive chronic myeloid leukemia (ph + cml); Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml) by administering nilotinib dispersed in a fruit preparation

Dosage: CAPSULE;ORAL

How can I launch a generic of TASIGNA before it's patent expiration?
More Information on Dosage

28. List of Tekamlo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8613949 NOVARTIS Galenical formulations of organic compounds
Dec, 2029

(6 years from now)

Drugs and Companies using ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE ingredient

Market Authorisation Date: 26 August, 2010

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

29. List of Travatan Z drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8323630 NOVARTIS Self-preserved aqueous pharmaceutical compositions
Sep, 2027

(4 years from now)

US8388941 NOVARTIS Self preserved aqueous pharmaceutical compositions
Sep, 2027

(4 years from now)

US8268299 NOVARTIS Self preserved aqueous pharmaceutical compositions
Oct, 2029

(6 years from now)

Drugs and Companies using TRAVOPROST ingredient

Market Authorisation Date: 21 September, 2006

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of TRAVATAN Z before it's patent expiration?
More Information on Dosage

30. List of Triesence drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8211880 NOVARTIS Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
Mar, 2029

(6 years from now)

US8128960 NOVARTIS Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
Dec, 2029

(6 years from now)

Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient

Market Authorisation Date: 29 November, 2007

Treatment: Visualization during vitrectomy procedures; Treatment of ophthalmic disorders

Dosage: INJECTABLE;INTRAVITREAL

More Information on Dosage

31. List of Tykerb drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8821927 NOVARTIS Pharmaceutical composition
Sep, 2029

(6 years from now)

Drugs and Companies using LAPATINIB DITOSYLATE ingredient

Market Authorisation Date: 13 March, 2007

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of TYKERB before it's patent expiration?
More Information on Dosage

32. List of Tyzeka drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7589079 NOVARTIS Crystalline and amorphous forms of beta-L-2′-deoxythymidine
Sep, 2023

(7 months from now)

US7858594 NOVARTIS Crystalline and amorphous forms of beta-L-2′-deoxythymidine
Sep, 2023

(7 months from now)

Drugs and Companies using TELBIVUDINE ingredient

Market Authorisation Date: 25 October, 2006

Treatment: Treatment of chronic hepatitis b in adult patients

Dosage: TABLET;ORAL

More Information on Dosage

33. List of Utibron drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6878721 NOVARTIS Beta2-adrenoceptor agonists
Feb, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8479730 NOVARTIS Inhaler device
Oct, 2028

(5 years from now)

US8182838 NOVARTIS Dry powder composition comprising co-jet milled particles for pulmonary inhalation
Oct, 2028

(5 years from now)

Drugs and Companies using GLYCOPYRROLATE; INDACATEROL MALEATE ingredient

Market Authorisation Date: 29 October, 2015

Treatment: Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd)

Dosage: POWDER;INHALATION

More Information on Dosage

34. List of Valturna drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8168616 NOVARTIS Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
Jul, 2026

(3 years from now)

Drugs and Companies using ALISKIREN HEMIFUMARATE; VALSARTAN ingredient

Market Authorisation Date: 16 September, 2009

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

35. List of Vijoice drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8476268 NOVARTIS Pyrrolidine-1,2-dicarboxamide derivatives
Sep, 2029

(6 years from now)

US8227462 NOVARTIS Pyrrolidine-1,2-dicarboxamide derivatives
Sep, 2030

(7 years from now)

CN102149711B NOVARTIS Organic Compounds
Sep, 2029

(6 years from now)

CN102149711A NOVARTIS Organic Compounds
Sep, 2029

(6 years from now)

IN307469B NOVARTIS The Compound (S)-Pyrrolidine-1,2-Dicarboxylic Acid 2-Amide-1- ({4-Methyl-5-[2-(2,2,2-Trifluoro-1,1-Dimethyl-Ethyl)- Pyridin-4-Yl]-Thiazol-2-Yl}-Amide)
Sep, 2029

(6 years from now)

EP2331537A1 NOVARTIS 1-((5-Heteroarylthiazol-2-Yl)Aminocarbonyl)Pyrrolidine-2-Carboxamide Derivatives As Phosphatidylinositol 3-Kinase (Pi3K) Inhibitors Useful In The Treatment Of Proliferative Diseases
Sep, 2029

(6 years from now)

EP2331537B1 NOVARTIS 1-((5-Heteroarylthiazol-2-Yl)Aminocarbonyl)Pyrrolidine-2-Carboxamide Derivatives As Phosphatidylinositol 3-Kinase (Pi3K) Inhibitors Useful In The Treatment Of Proliferative Diseases
Sep, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 24, 2024

Drugs and Companies using ALPELISIB ingredient

NCE-1 date: May, 2023

Market Authorisation Date: 05 April, 2022

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

36. List of Votrient drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7105530 NOVARTIS Pyrimidineamines as angiogenesis modulators
Oct, 2023

(8 months from now)

Drugs and Companies using PAZOPANIB HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2009

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

37. List of Xiidra drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7745460 NOVARTIS Modulators of cellular adhesion
Nov, 2024

(1 year, 9 months from now)

US7928122 NOVARTIS Modulators of cellular adhesion
Nov, 2024

(1 year, 9 months from now)

US7314938 NOVARTIS Modulators of cellular adhesion
Mar, 2025

(2 years from now)

US8084047 NOVARTIS Compositions and methods for treatment of eye disorders
May, 2026

(3 years from now)

US9890141 NOVARTIS Crystalline pharmaceutical and methods of preparation and use thereof
Oct, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216174 NOVARTIS Modulators of cellular adhesion
Nov, 2024

(1 year, 9 months from now)

US10124000 NOVARTIS Modulators of cellular adhesion
Nov, 2024

(1 year, 9 months from now)

US7790743 NOVARTIS Modulators of cellular adhesion
Nov, 2024

(1 year, 9 months from now)

US8592450 NOVARTIS Compositions and methods for treatment of eye disorders
May, 2026

(3 years from now)

US8367701 NOVARTIS Crystalline pharmaceutical and methods of preparation and use thereof
Apr, 2029

(6 years from now)

US9447077 NOVARTIS Crystalline pharmaceutical and methods of preparation and use thereof
Apr, 2029

(6 years from now)

US8168655 NOVARTIS Compositions and methods for treatment of eye disorders
May, 2029

(6 years from now)

US9353088 NOVARTIS Crystalline pharmaceutical and methods of preparation and use thereof
Oct, 2030

(7 years from now)

US8927574 NOVARTIS Crystalline pharmaceutical and methods of preparation and use thereof
Nov, 2030

(7 years from now)

US9085553 NOVARTIS LFA-1 inhibitor and methods of preparation and polymorph thereof
Jul, 2033

(10 years from now)

US11058677 NOVARTIS LFA-1 inhibitor formulations
Dec, 2033

(10 years from now)

Drugs and Companies using LIFITEGRAST ingredient

Market Authorisation Date: 11 July, 2016

Treatment: Treatment of the signs and symptoms of dry eye disease (ded); Treatment of signs and symptoms of dry eye disease (ded)

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of XIIDRA before it's patent expiration?
More Information on Dosage

38. List of Zometa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8324189 NOVARTIS Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
May, 2025

(2 years from now)

US8324189

(Pediatric)

NOVARTIS Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
Nov, 2025

(2 years from now)

US7932241 NOVARTIS Pharmaceutical products comprising bisphosphonates
Feb, 2028

(5 years from now)

Drugs and Companies using ZOLEDRONIC ACID ingredient

Market Authorisation Date: 20 August, 2001

Treatment: Multiple myeloma; Bone metastases; Hypercalcemia of malignancy

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of ZOMETA before it's patent expiration?
More Information on Dosage

39. List of Zykadia drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8188276 NOVARTIS 2,4-pyrimidinediamine compounds and their uses
Jan, 2023

(a day from now)

US8835430 NOVARTIS 2,4-pyrimidinediamine compounds and their uses
Jan, 2023

(a day from now)

US9018204 NOVARTIS 2,4-pyrimidinediamine compounds and their uses
Jan, 2023

(a day from now)

US9416112 NOVARTIS 2,4-pyrimidinediamine compounds and their uses
Jan, 2023

(a day from now)

US7893074 NOVARTIS 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
Apr, 2026

(3 years from now)

US8399450 NOVARTIS Compounds and compositions as protein kinase inhibitors
Nov, 2027

(4 years from now)

US7964592 NOVARTIS 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
Apr, 2028

(5 years from now)

US8039479 NOVARTIS Compounds and compositions as protein kinase inhibitors
Jun, 2030

(7 years from now)

US9309229 NOVARTIS Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
Jan, 2032

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8377921 NOVARTIS Compounds and compositions as protein kinase inhibitors
Nov, 2027

(4 years from now)

US8703787 NOVARTIS Methods of using ALK inhibitors
Feb, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 26, 2024

Drugs and Companies using CERITINIB ingredient

Market Authorisation Date: 29 April, 2014

Treatment: Treatment of a cancer mediated by an anaplastic lymphoma kinase (alk)

Dosage: CAPSULE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in